BOSTON & LONDON--(BUSINESS WIRE)--Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, welcomes the recent announcement by the Centers for ...

The FDA revised its emergency use authorization for EVUSHELD™, tixagevimab co-packaged with cilgavimab. The initial dose authorized has been changed to 600 mg for pre-exposure prevention of COVID-19.